Protalix BioTherapeutics (PLX) Change in Receivables (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Change in Receivables of -$6.4 million for Q1 2026, down 381.67% year-over-year from $2.3 million in Q1 2025, and down 9.02% quarter-over-quarter from -$5.9 million in Q4 2025.
Protalix BioTherapeutics (PLX) Change in Receivables (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$6.4 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 381.67% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$2.8 million (down 263.91% YoY), while the FY2025 annual figure was $5.9 million, up 354.21% from the prior year.
- Change in Receivables for Q1 2026 stood at -$6.4 million, down from -$5.9 million in the prior quarter.
- The five-year high for Change in Receivables was $7.1 million in Q2 2024, with the low at -$8.4 million in Q3 2024.
- The 5-year median for Change in Receivables is $752000.0 (2024), against an average of -$71352.9.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables soared 254.98% in 2023, then plunged 881.65% in 2025.
- Protalix BioTherapeutics' Change in Receivables stood at -$4.5 million in 2022, then climbed by 16.41% to -$3.8 million in 2023, then jumped by 120.0% to $752000.0 in 2024, then slumped by 881.65% to -$5.9 million in 2025, then fell by 9.02% to -$6.4 million in 2026.
- Business Quant data shows PLX's Change in Receivables at -$6.4 million in Q1 2026, -$5.9 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 15.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.03 Mn |
| Jun 30, 2026 | 15.03 Mn |
| Mar 31, 2026 | -6.41 Mn |
| Mar 31, 2026 | -6.41 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 4.64 Mn |
| Jun 30, 2025 | 4.64 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 752,000.00 |
| Dec 31, 2024 | 752,000.00 |
| Sep 30, 2024 | -8.38 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Jun 30, 2024 | 7.05 Mn |
| Mar 31, 2024 | -1.75 Mn |
| Mar 31, 2024 | -1.75 Mn |